Stocks · News reference
Kura Oncology Announces Updated Phase 1A Results From Ongoing FIT-001 Clinical Trial; Data Demonstrate Encouraging And Durable Clinical Activity Of Darlifarnib Plus Cabozantinib In Cabozantinib-Naïve Patients With Advanced Clear Cell Renal Cell Carcinoma
– Response rates up to 50% across evaluated dose levels and median PFS of 13 months observed in pre-treated, cabozantinib-naïve, locally advanced or metastatic ccRCC patients –– Activity compares favorably with
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 27, 2026, 10:34 AM
- Checked
- Jul 27, 2026, 10:34 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Why Cadeler Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
Shares of Cadeler A/S (NYSE: CDLR) surged in pre-market trading after reporting strong financial results for the first half of 2026. Revenue and profit increased significantly, and full-year guidance was maintained. Other stocks also moved in pre-market trading.
Read original at benzingaCitizens Reiterates Market Outperform on Kura Oncology, Maintains $24 Price Target
Read original at benzingaDuos Technologies Posts Upbeat Q2 Results, Joins Amylyx Pharmaceuticals, Weave Communications And Other Big Stocks Moving Higher On Tuesday
US stocks down, Nasdaq falls 300+ points. Duos Tech shares rise on better Q2 results. Many other big stocks gain, including Duolingo, Intuit, and Newsmax.
Read original at benzinga